CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC)....

Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173...

Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study....

Immunotherapy in non-small cell lung cancer (NSCLC)...

Landscape of Biosimilars in Supportive and Therapeutic Cancer Care...

IMMUNOTHERAPY IN LYMPHOMAS / CHECKPOINT INHIBITORS...

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOWUP OF THE PHASE 2 CHECKMATE 205 TRIAL...

PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY...

BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)...

Highlights of the congress...

The effect of an immunomodulatory drug on the viability and surface molecule expression of chronic lymphocytic leukemia cells...

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN...

CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF AGGRESSIVE B CELL LYMPHOMAS...

ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV...

Can the mutational landscape of AML inform targeted treatment?...

Shifting treatment paradigms means in DLBCL...

Update on follicular lymphoma: Time beyond chemotherapy?...

Biosimilars for Hematologic Malignancies: The Path to Sustainable Care;

The role of biosimilars in promoting sustainability of care [presentation and panel discussion]...

A look at biosimilars development...